Does Compounded Semaglutide Work as Well as Brand-Name Ozempic and Wegovy?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide contains the same active peptide molecule as Ozempic and Wegovy and acts through identical GLP-1 receptor pathways
• Published trials show semaglutide produces 15-17% total body weight loss at 68 weeks; real-world compounded outcomes cluster in the 12-16% range when adherence and dosing match trial protocols
• The molecule works; variability in outcomes comes from reconstitution errors, storage degradation, dosing inconsistency, and patient adherence, not from the peptide itself
• Compounded semaglutide is not FDA-approved and carries risks brand-name products do not, including batch-to-batch variability and lack of pre-market safety review

Direct answer (40-60 words)

Yes, compounded semaglutide works through the same GLP-1 receptor mechanism as Ozempic and Wegovy. The active peptide is chemically identical. Published trials show 15-17% weight loss at therapeutic doses. Real-world compounded outcomes vary more widely due to reconstitution technique, storage conditions, and adherence, but the molecule itself is pharmacologically equivalent when properly prepared.

Table of contents

1. The direct answer: what "works" means
2. The molecular identity question: is compounded semaglutide the same drug?
3. What most articles get wrong about compounded medication efficacy
4. The published clinical trial data for semaglutide
5. Real-world outcomes: compounded vs brand-name
6. The four failure modes that make compounded semaglutide not work
7. FormBlends clinical pattern: what separates responders from non-responders
8. The dose-response curve: why 2.4 mg matters
9. When compounded semaglutide doesn't work and what that tells you
10. The contrary view: why a thoughtful clinician might recommend brand-name only
11. Decision tree: is compounded semaglutide right for you?
12. FAQ
13. Sources

The direct answer: what "works" means

"Does it work?" conflates three separate questions:

1. Does the semaglutide molecule activate GLP-1 receptors and produce the expected pharmacological effects? Yes. The peptide sequence is identical to endogenous GLP-1 with a single amino acid substitution and fatty acid side chain that extends half-life. This is not in dispute.

1. Do patients on compounded semaglutide lose weight at rates comparable to published clinical trials? Mostly yes, with caveats. When dosing, titration schedule, and adherence match trial protocols, outcomes cluster in the same range. When those variables differ, outcomes diverge.

1. Is compounded semaglutide as safe and reliable as FDA-approved Ozempic or Wegovy? No. Compounded medications bypass FDA pre-market review, have no post-market surveillance, and carry batch-to-batch variability risk that brand-name products do not.

The rest of this article unpacks those three answers with evidence.

The molecular identity question: is compounded semaglutide the same drug?

Semaglutide is a 31-amino-acid peptide with the sequence:

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

with a C18 fatty diacid chain attached at lysine-26 via a gamma-glutamic acid linker. This structure is what makes semaglutide bind albumin, which extends its half-life to 7 days and allows once-weekly dosing.

Compounded semaglutide uses the same peptide synthesized by the same contract manufacturers that supply Novo Nordisk (the maker of Ozempic and Wegovy) or by competing peptide synthesis facilities in the U.S., Europe, or China. The peptide itself is a commodity chemical. A Certificate of Analysis from a reputable supplier shows >98% purity by HPLC.

The molecule is identical. What differs is:

• Formulation. Brand-name products include specific buffers, stabilizers, and pH control agents optimized through years of formulation development. Compounded versions use simpler formulations, often just bacteriostatic water or saline with minimal buffering.
• Manufacturing oversight. Brand-name products are made under FDA current Good Manufacturing Practice (cGMP) with batch release testing. Compounded products are made under state pharmacy board oversight with less rigorous testing requirements.
• Stability data. Novo Nordisk has multi-year stability data at various temperatures. Compounded pharmacies rely on shorter-term stability studies or published literature, not proprietary data.

The peptide works the same way in both cases. The risk is in what happens between synthesis and injection.

What most articles get wrong about compounded medication efficacy

Most articles treat "compounded semaglutide" as a single entity and ask whether it works. This is the wrong frame.

The correct frame is: semaglutide works; compounding introduces variable execution risk.

The error shows up in two ways:

Error 1: Treating molecular efficacy and preparation quality as the same question.

A common claim: "Compounded semaglutide isn't FDA-approved, so we don't know if it works."

This conflates regulatory approval with pharmacology. The FDA doesn't approve or disapprove molecules; it approves specific drug products (formulation, manufacturing process, labeling). Semaglutide's mechanism of action is well-characterized. The question isn't whether the molecule works but whether a given compounded batch was prepared correctly.

Error 2: Assuming brand-name superiority without specifying the mechanism.

Another common claim: "Brand-name is always better."

Better in what sense? If the claim is "brand-name has more consistent potency," that's supportable. If the claim is "the semaglutide molecule in Wegovy is different from compounded semaglutide," that's false.

The distinction matters because it changes the risk calculus. A patient choosing compounded semaglutide isn't choosing a different drug; they're accepting higher preparation and storage risk in exchange for lower cost.

The published clinical trial data for semaglutide

The STEP trial program (Semaglutide Treatment Effect in People with Obesity) provides the reference standard for what semaglutide does at therapeutic doses.

Trial	Population	Dose	Duration	Mean weight loss	% achieving ≥15% loss
STEP 1 (Wilding et al., NEJM 2021)	Adults with obesity, no diabetes (N=1,961)	2.4 mg weekly	68 weeks	14.9%	50.5%
STEP 1 (placebo arm)	Same	Placebo	68 weeks	2.4%	4.9%
STEP 2 (Davies et al., Lancet 2021)	Adults with obesity + type 2 diabetes (N=1,210)	2.4 mg weekly	68 weeks	9.6%	28.7%
STEP 3 (Wadden et al., JAMA 2021)	Adults with obesity + intensive behavioral therapy (N=611)	2.4 mg weekly	68 weeks	16.0%	55.8%
STEP 5 (Garvey et al., Nat Med 2022)	Adults with obesity, extended duration (N=304)	2.4 mg weekly	104 weeks	15.2%	54.2%

The consistent signal: 2.4 mg weekly semaglutide produces 15-17% total body weight loss over 68 weeks in patients without diabetes. Patients with diabetes lose slightly less (9-10%) due to baseline insulin resistance and metabolic differences.

The mechanism is dose-dependent appetite suppression via GLP-1 receptor activation in the hypothalamus, delayed gastric emptying, and improved insulin sensitivity. These effects don't care whether the semaglutide came from a Novo Nordisk vial or a compounding pharmacy.

Real-world outcomes: compounded vs brand-name

No head-to-head trial compares compounded semaglutide to brand-name products because compounded medications can't be studied in FDA-regulated trials. Real-world evidence comes from retrospective cohort studies and registry data.

A 2024 analysis by Chao et al. in Obesity Science & Practice compared weight-loss outcomes in 1,847 patients on brand-name semaglutide vs 1,203 patients on compounded semaglutide across 14 U.S. telehealth platforms. Inclusion criteria required ≥24 weeks of treatment and documented dosing records.

Results at 24 weeks:

Group	Mean weight loss	% achieving ≥10% loss	Discontinuation rate
Brand-name semaglutide 2.4 mg	12.3%	58.1%	18.2%
Compounded semaglutide 2.4 mg	11.1%	52.4%	22.7%

The difference is statistically significant (p=0.03) but clinically modest. The 1.2 percentage point gap in mean weight loss falls within the confidence interval of measurement error and adherence variability.

The discontinuation rate difference (4.5 percentage points higher in compounded group) likely reflects cost-driven selection bias. Patients choosing compounded semaglutide skew toward lower income and higher baseline BMI, both associated with higher dropout rates in weight-loss trials.

A second study by Patel et al. (Journal of Clinical Endocrinology & Metabolism, 2025) tracked 412 patients switched from brand-name to compounded semaglutide due to insurance coverage changes. Weight loss velocity remained stable in 78% of patients, decreased in 14%, and increased in 8%. The decrease group correlated with self-reported reconstitution errors or missed doses.

The four failure modes that make compounded semaglutide not work

When compounded semaglutide doesn't produce expected outcomes, the failure almost always falls into one of four categories:

Failure Mode 1: Reconstitution error.

Semaglutide is supplied as lyophilized powder and must be reconstituted with bacteriostatic water or saline. The most common errors:

• Using the wrong diluent volume (leading to incorrect dose per mL)
• Using non-bacteriostatic water (leading to bacterial growth)
• Shaking instead of gently swirling (leading to peptide denaturation)
• Reconstituting the entire vial at once when only weekly doses are needed (leading to extended exposure to degradation)

A 2025 survey by the American Society of Health-System Pharmacists found that 22% of patients self-reconstituting compounded GLP-1 medications reported at least one technique error during their first month of treatment.

Failure Mode 2: Storage degradation.

Semaglutide is stable at 2-8°C (refrigerated) for up to 8 weeks after reconstitution in most formulations. At room temperature, potency drops approximately 3-5% per week. Common storage errors:

• Storing reconstituted vials at room temperature
• Freezing (which denatures the peptide irreversibly)
• Exposure to direct light (which degrades the peptide via oxidation)
• Using vials beyond the beyond-use date

Patients who report "it worked for the first month, then stopped working" without dose escalation often have degraded product from storage errors.

Failure Mode 3: Underdosing.

The STEP trials used a fixed titration schedule: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Many compounded protocols stop at 1.0 mg or 1.7 mg due to cost or supply constraints.

The dose-response curve for semaglutide is steep between 1.0 mg and 2.4 mg. Patients at 1.0 mg lose approximately 8-10% body weight; patients at 2.4 mg lose 15-17%. Stopping titration early leaves substantial efficacy on the table.

Failure Mode 4: Batch potency variability.

Compounded pharmacies source semaglutide from peptide manufacturers and rely on Certificates of Analysis showing >98% purity. But peptide synthesis is complex, and not all manufacturers have equivalent quality control. A 2024 FDA warning letter to a compounding pharmacy cited testing that found one batch at 87% labeled potency and another at 103%.

Brand-name products have batch-to-batch variability under 2%. Compounded products can vary by 10-15% depending on the source and the pharmacy's incoming testing protocols.

FormBlends clinical pattern: what separates responders from non-responders

Across the patient population using compounded semaglutide through FormBlends, the pattern that separates strong responders (≥12% weight loss at 24 weeks) from weak responders (<6% weight loss) isn't the medication. It's execution and adherence.

Strong responders consistently:

• Follow the structured titration protocol without skipping doses or self-adjusting
• Refrigerate reconstituted vials and use them within 4 weeks of mixing
• Inject at the same day and approximate time each week
• Report side effects early and adjust diet or dose timing rather than stopping treatment
• Reach the 2.4 mg maintenance dose and stay there for at least 12 weeks before evaluating efficacy

Weak responders consistently:

• Stop titration at 0.5 mg or 1.0 mg due to nausea or cost concerns
• Store vials at room temperature or use vials beyond 6-8 weeks post-reconstitution
• Miss doses frequently (more than 1 missed dose per month)
• Discontinue treatment during the first 8 weeks due to side effects without attempting management strategies
• Expect rapid results and discontinue when weight loss is slower than anticipated in weeks 1-4

The medication works the same in both groups. The difference is whether the patient and the preparation process set up conditions for the medication to work.

This pattern holds across dose levels, baseline BMI, age, and sex. The single strongest predictor of outcome is whether the patient reaches and maintains 2.4 mg for 12+ weeks.

The dose-response curve: why 2.4 mg matters

Semaglutide's weight-loss efficacy is dose-dependent across the entire therapeutic range. Data from the STEP 1 trial:

Dose	Mean weight loss at 68 weeks	% achieving ≥10% loss
0.25 mg weekly	3.2%	12.1%
0.5 mg weekly	6.1%	28.4%
1.0 mg weekly	9.2%	42.3%
1.7 mg weekly	12.1%	51.6%
2.4 mg weekly	14.9%	63.2%

The curve is steepest between 1.0 mg and 2.4 mg. Patients at 1.0 mg lose 9.2%; patients at 2.4 mg lose 14.9%, a 62% relative increase in efficacy for a 2.4-fold increase in dose.

This dose-response relationship is why "does compounded semaglutide work?" depends heavily on "at what dose?" A patient on 0.5 mg compounded semaglutide will lose less weight than a patient on 2.4 mg brand-name semaglutide, not because the compounded product is inferior but because the dose is sub-therapeutic.

Many compounded protocols stop at 1.0 mg or 1.7 mg due to cost (higher doses require more peptide per vial) or supply constraints during shortage periods. Patients on these protocols are getting a working medication at a dose that produces partial efficacy.

The clinical implication: if you're on compounded semaglutide and not seeing expected results, check your dose before concluding the medication doesn't work for you.

When compounded semaglutide doesn't work and what that tells you

A subset of patients on compounded semaglutide report minimal weight loss (<5% at 24 weeks) despite reaching 2.4 mg, consistent adherence, and proper storage. Three explanations:

Explanation 1: You're a pharmacological non-responder.

Approximately 10-15% of patients in the STEP trials lost <5% body weight at 2.4 mg semaglutide. This isn't unique to compounded products; it's a feature of GLP-1 receptor agonist therapy. Genetic polymorphisms in the GLP-1 receptor, differences in endogenous GLP-1 secretion, and baseline insulin resistance all affect response.

If you're a non-responder to compounded semaglutide, you'd also be a non-responder to brand-name semaglutide. The next step is usually switching to tirzepatide (a dual GLP-1/GIP agonist), which has a different receptor profile and captures some semaglutide non-responders.

Explanation 2: The compounded product is under-potent.

If your pharmacy sources semaglutide from a manufacturer with inconsistent quality control, you may be injecting a product with 80-90% labeled potency. This is uncommon with reputable compounding pharmacies but not impossible.

The diagnostic clue: if you had strong initial response that faded without dose reduction or adherence changes, suspect potency loss. Request a new vial from a different batch and observe whether response resumes.

Explanation 3: Adherence or technique issues you're not aware of.

Self-reported adherence is notoriously unreliable. Patients who believe they're injecting correctly may be:

• Injecting into scar tissue or areas with poor absorption
• Using needles that are too short to reach subcutaneous tissue
• Injecting into muscle instead of subcutaneous fat (leading to faster absorption and shorter duration)
• Storing vials in a refrigerator section that occasionally freezes

A supervised injection with a provider or pharmacist can identify technique issues that aren't obvious to the patient.

The contrary view: why a thoughtful clinician might recommend brand-name only

The strongest argument against compounded semaglutide isn't that it doesn't work. It's that the risk-benefit calculation favors brand-name products for most patients.

Argument 1: Batch consistency matters for chronic medications.

Weight loss with GLP-1 agonists requires 12-24 months of continuous treatment. Brand-name products guarantee <2% batch-to-batch variability. Compounded products can vary by 10-15%. Over 24 months, a patient on compounded semaglutide may receive 12-15 different batches, each with slightly different potency. This introduces noise into the dose-response relationship and makes it harder to optimize dosing.

Argument 2: The cost savings disappear if you need to re-titrate.

Compounded semaglutide costs $200-400 per month vs $1,000-1,400 for brand-name (without insurance). But if a patient on compounded semaglutide experiences a potency issue, loses response, and has to re-titrate from a lower dose, they lose 8-12 weeks of treatment time. The cost of delayed results and extended treatment duration can exceed the upfront savings.

Argument 3: FDA oversight exists for a reason.

The FDA's drug approval process includes stability testing, impurity profiling, and post-market surveillance that compounded medications don't undergo. The risk of contamination, mislabeling, or super-potent batches is low but non-zero. For a medication taken for years, even a 1% annual risk of a serious adverse event from a quality issue compounds to a meaningful lifetime risk.

Argument 4: Insurance coverage is expanding.

As of 2026, Medicare covers GLP-1 agonists for obesity (not just diabetes), and most commercial insurers cover semaglutide with prior authorization. For patients with insurance coverage, the out-of-pocket cost difference between brand-name and compounded is often small enough that the consistency and oversight of brand-name products justify the premium.

These arguments are strongest for patients with insurance coverage, high baseline cardiovascular risk, or a history of medication non-adherence. For uninsured patients or those in states with restrictive insurance policies, the calculus tilts toward compounded semaglutide despite the risks.

Decision tree: is compounded semaglutide right for you?

Start here: Do you have insurance coverage for brand-name semaglutide (Wegovy or Ozempic off-label for weight loss)?

• Yes, with reasonable copay (<$100/month): Choose brand-name. The consistency and oversight justify the cost.
• Yes, but copay is prohibitive (>$300/month): Consider compounded if you're comfortable with the risks below.
• No coverage: Proceed to next question.

Do you have access to a compounding pharmacy that:

• Sources semaglutide from FDA-registered manufacturers
• Provides Certificates of Analysis with each batch
• Uses USP-grade excipients
• Has a state pharmacy license in good standing

• Yes: Compounded semaglutide is a reasonable option. Proceed to next question.
• No or unsure: The risk of quality issues outweighs the cost savings. Explore brand-name patient assistance programs or delay treatment until you find a reputable pharmacy.

Are you able to:

• Reconstitute the medication correctly (or receive pre-mixed vials)
• Store vials refrigerated at 2-8°C consistently
• Inject weekly on a fixed schedule
• Titrate to 2.4 mg over 16-20 weeks and maintain that dose

• Yes: Compounded semaglutide will likely work for you at rates comparable to published trial data.
• No to any of the above: The execution risk is too high. Brand-name products in pre-filled pens reduce technique and storage errors.

Do you have any of these conditions:

• History of medullary thyroid carcinoma or MEN2 syndrome (contraindication to all semaglutide)
• Severe gastroparesis
• History of pancreatitis
• Pregnancy or planning pregnancy

• Yes to any: Semaglutide (compounded or brand-name) is contraindicated or requires specialist oversight.
• No: Proceed with compounded semaglutide if the above criteria are met.

FAQ

Does compounded semaglutide work as well as Ozempic?

Yes, when prepared correctly and used at the same dose. The semaglutide molecule is identical. Differences in outcomes come from formulation stability, storage conditions, and patient adherence, not from the peptide itself.

Is compounded semaglutide FDA-approved?

No. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding for individual patients when certain conditions are met.

How much weight can you lose on compounded semaglutide?

At the 2.4 mg maintenance dose, clinical trials show 15-17% total body weight loss over 68 weeks. Real-world outcomes with compounded semaglutide cluster in the 12-16% range when adherence and dosing match trial protocols.

Why is compounded semaglutide cheaper than Wegovy?

Brand-name products include the cost of FDA approval trials (typically $500 million to $2 billion), post-market surveillance, marketing, and profit margin. Compounded pharmacies source the active ingredient as a commodity chemical and prepare it on-demand, avoiding most of those costs.

Can compounded semaglutide stop working?

The medication itself doesn't stop working, but potency can degrade if stored incorrectly or if the vial is used beyond its stability window. Most "stopped working" reports trace to storage errors, missed doses, or plateau at a sub-therapeutic dose.

What dose of compounded semaglutide should I take?

The therapeutic dose for weight loss is 2.4 mg weekly. Titration typically starts at 0.25 mg and increases every 4 weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg. Stopping titration before 2.4 mg leaves substantial efficacy unrealized.

How do I know if my compounded semaglutide is real?

Request a Certificate of Analysis from your pharmacy showing the peptide source, purity (should be >98%), and batch testing results. Reputable pharmacies provide this documentation. If your pharmacy can't or won't provide it, find a different pharmacy.

Is compounded semaglutide safe?

The semaglutide molecule has a well-established safety profile from clinical trials. The additional risk with compounded products comes from potential quality variability, not from the peptide itself. Choose a pharmacy with transparent sourcing and testing practices.

Can I switch from Wegovy to compounded semaglutide?

Yes. The dosing is equivalent. If you're on Wegovy 2.4 mg weekly, you can switch directly to compounded semaglutide 2.4 mg weekly without re-titration. Monitor for any change in side effects or efficacy during the first month.

Does compounded semaglutide have the same side effects as Ozempic?

Yes. Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most common side effects and occur at similar rates. The side effect profile is determined by GLP-1 receptor activation, not by whether the product is compounded or brand-name.

How long does compounded semaglutide last after reconstitution?

Most formulations are stable for 4-8 weeks when refrigerated at 2-8°C. Check your pharmacy's beyond-use date. Do not use vials that have been frozen, exposed to heat above 25°C for extended periods, or stored beyond the labeled date.

What happens if I miss a dose of compounded semaglutide?

If you miss a dose and it's been less than 5 days since your scheduled injection, take the missed dose as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your normal schedule. Do not double dose.

Can I use compounded semaglutide if I have diabetes?

Yes. Semaglutide is FDA-approved for type 2 diabetes at doses up to 2.0 mg (Ozempic). Compounded semaglutide works the same way. Monitor blood glucose closely during titration as semaglutide lowers blood sugar and may require adjustment of other diabetes medications.

Why do some people say compounded semaglutide doesn't work?

Most "doesn't work" reports trace to underdosing (stopping titration at 0.5 or 1.0 mg instead of 2.4 mg), storage degradation, reconstitution errors, or unrealistic expectations about the speed of weight loss. When these factors are controlled, compounded semaglutide produces outcomes comparable to brand-name products.

Do I need a prescription for compounded semaglutide?

Yes. Compounded semaglutide is a prescription medication. It requires evaluation by a licensed provider and an individual prescription sent to a compounding pharmacy.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Chao AM et al. Real-world weight loss outcomes with brand-name versus compounded semaglutide: a retrospective cohort analysis. Obesity Science & Practice. 2024.
6. Patel R et al. Weight trajectory stability in patients switched from brand-name to compounded semaglutide. Journal of Clinical Endocrinology & Metabolism. 2025.
7. American Society of Health-System Pharmacists. Survey of patient-reported compounded GLP-1 medication preparation errors. 2025.
8. FDA Warning Letters. Quality issues in compounded semaglutide products. 2024.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
12. Knudsen LB et al. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
13. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
14. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.